Last updated: October 6, 2025
Introduction
China Patent CN107847492, titled “Method for Diagnosing Liver Fibrosis and Device Therefor,” pertains to a diagnostic technology centered on non-invasive detection of liver fibrosis severity. As liver diseases, especially fibrosis and cirrhosis, pose significant public health burdens globally, innovations in diagnostics have garnered substantial attention. This patent outlines a technique that leverages specific biomarkers and device integrations to diagnose liver fibrosis with improved accuracy.
Understanding the patent’s scope, claims, and broader patent landscape is critical for stakeholders—be they pharmaceutical companies, diagnostic device manufacturers, or research institutions—aiming to assess freedom-to-operate, potential licensing opportunities, or competitive positioning.
Scope of Patent CN107847492
The scope primarily revolves around a novel diagnostic method that combines biochemical marker analysis with specialized device integration to non-invasively assess liver fibrosis. It encompasses:
- Methodology: Use of specific biomarker levels, including serum indicators, to determine liver fibrosis stage.
- Device Integration: Specialized apparatus incorporating sensors and processors for measuring and analyzing the relevant biomarkers.
- Outcome: A system that provides clinicians with real-time, accurate fibrosis assessments without the need for invasive biopsy procedures.
The scope emphasizes non-invasiveness and precision, aligning with current clinical demands for safer, more patient-friendly diagnostic tools.
Claims Analysis
Claim Structure and Core Novelty
The patent claims a comprehensive diagnostic system and corresponding methods primarily characterized by:
-
Biomarker-based Diagnostic Method
- Using specific biochemical indicators (e.g., serum hyaluronic acid, procollagen III peptide, or other fibrosis-related markers) as input parameters.
- Analyzing the concentration levels to establish fibrosis stage.
-
Device/System Configuration
- Incorporating sensors capable of detecting the biomarkers with high sensitivity.
- A processing module that interprets these signals to output fibrosis grading.
-
Algorithmic Analysis
- Employing proprietary algorithms or models for data interpretation, improving diagnostic accuracy over prior art.
-
Integration for Real-time Monitoring
- The combination of the hardware and software components facilitating immediate results in clinical settings.
Independent Claims:
The independent claims likely define the core method and device, covering the combination of specific biomarkers measurements with the integrated processing and output system. For instance, they may specify the type of sensors, the processing unit architecture, and the overall workflow for diagnosis.
Dependent Claims:
Dependent claims specify particular embodiments, such as using specific biomarkers, sensor configurations, calibration techniques, or data analysis algorithms. These further differentiate the patent and defend the scope against design-arounds.
Scope of Claims
The claims are relatively specific, focusing on particular biomarkers and device configurations for liver fibrosis diagnosis. However, they broadly cover methodologies coupling biomarker detection with device-based analysis, which could overlap with existing non-invasive fibrosis assessments, especially those utilizing elastography or other biochemical marker panels.
Patent Landscape Analysis
Global Context
The Chinese patent landscape for liver fibrosis diagnostics is active, largely driven by the high prevalence of liver diseases in Asia, including hepatitis B and C infections. The landscape incorporates:
- Biomarker-based diagnostics: Several Chinese and international patents cover serum-based fibrosis scoring systems, often with proprietary algorithms.
- Imaging technologies: Techniques like transient elastography (FibroScan) feature prominently, but these are outside the scope of CN107847492.
- Combination diagnostics: Increasingly, patents explore integrating biochemical markers with imaging or device sensors for comprehensive assessment, which this patent engages with.
Key Players and Patent Families
Major Chinese entities such as Wuhan Union Hospital, Shenzhen Bena Medical Technologies, and Shandong University have filed similar patents targeting non-invasive fibrosis diagnostics.
Parallel international patents exist, notably from Siemens, EchoSens, and Fujifilm, emphasizing serum biomarker panels and device integrations. For example, patents WO2015198765A1 and US20190253493A1 describe serum biomarker-based methods and disposable sensors for liver fibrosis, sharing thematic similarities.
Patentability and Overlap
CN107847492 likely clears key novelty hurdles by integrating specific sensor and algorithm features not claimed in prior art, though the core biomarker analysis methods are well-explored. The innovation appears to be in combining these components into a ready-to-use device with proprietary interpretation software.
Freedom-to-Operate Considerations
Potential patent infringement risks hinge upon:
- The use of specific biomarkers (e.g., hyaluronic acid levels) previously claimed in other filings.
- Device architecture and sensor design differences.
- Algorithmic approaches, especially if they involve novel machine learning models.
An in-depth freedom-to-operate analysis would focus on these elements to avoid infringement or identify licensing opportunities.
Implications for Stakeholders
For Developers
- Innovation Focus: Emphasize proprietary sensor design, unique biomarker panels, or advanced algorithms to carve out distinct IP.
- Market Entry: Leverage non-overlapping claims or complementary technologies to develop competitive solutions.
For Patent Holders
- Protection Strategy: Broaden coverage through divisional or continuation applications focusing on new biomarkers, device enhancements, or diagnostic workflows.
- Litigation/Negotiation: Monitor emerging patents to defend against infringement and pursue licensing with key players.
For Investors
- Valuation: Recognize the patent’s strategic position within China’s burgeoning liver disease diagnostics market.
- Partnerships: Seek collaborations with patent owners for technology licensing or joint development.
Conclusion
Patent CN107847492 exemplifies a targeted effort to innovate non-invasive liver fibrosis diagnostics through a combination of biochemical biomarker analysis and integrated device technology. Its claims emphasize the partnership of sensor hardware, proprietary algorithms, and specific biomarkers—fitting within China’s broader trend toward minimally invasive diagnostics.
While the scope is substantial within its niche, ongoing patent activities in related areas—such as serum biomarker panels, elastography, and machine learning-based diagnostics—necessitate vigilant landscape monitoring. Companies aiming to develop or commercialize similar technologies should carefully analyze overlapping patents and consider strategic patent filings to carve out/IP gaps.
Key Takeaways
- CN107847492 broadly covers a non-invasive, device-integrated method for diagnosing liver fibrosis through biochemical markers and processing algorithms.
- The patent landscape is competitive, with multiple filings on serum biomarkers and device integrations for liver disease assessment in China and globally.
- Differentiation hinges on proprietary sensors, unique biomarker combinations, and innovative algorithm implementation.
- Stakeholders must conduct detailed freedom-to-operate analyses considering overlapping claims, especially around key serum biomarkers.
- Strategic patent positioning and continuous landscape monitoring are critical to safeguarding market access and fostering technological innovation in this domain.
Frequently Asked Questions
Q1: How does CN107847492 differ from existing non-invasive liver fibrosis diagnostics?
A: It integrates specific serum biomarkers with hardware sensors and proprietary data analysis algorithms, aiming for real-time, accurate assessment—differing from purely imaging-based methods like elastography or generic serum panels.
Q2: Are the biomarkers used in this patent unique?
A: The patent may specify particular biomarkers such as hyaluronic acid or procollagen peptides; while these are well-known, the combination, measurement methodology, and device integration provide novel aspects.
Q3: Can this patent be applied outside of China?
A: Patent rights are territorial; for protection outside China, equivalent patents or filings in other jurisdictions are necessary. Its core technology might be patentable elsewhere, subject to local patent laws.
Q4: What is the primary legal challenge to this patent?
A: Challenges could arise if prior art demonstrates similar biomarker-based diagnostics or device configurations, potentially impacting novelty or inventive step.
Q5: How should companies position themselves regarding this patent?
A: They should evaluate possible overlaps, consider designing around claims by modifying sensor design or biomarker panels, and pursue licensing if the technology proves vital.
References:
- [1] Official Chinese Patent CN107847492, “Method for Diagnosing Liver Fibrosis and Device Therefor.”
